Profile

Nicole Hamblett, PhD

Nicole Hamblett, PhD

Cystic Fibrosis Research

Academic Title: Research Associate Professor

Research Center: Center for Clinical and Translational Research

Nicole Mayer Hamblett, PhD, is an associate professor in the Division of Pulmonary Medicine at Seattle Children's Hospital and in the Departments of Pediatrics and Biostatistics at the University of Washington . Dr. Hamblett is a Co-Director of the Cystic Fibrosis Therapeutics Development Network Coordinating Center and the Seattle Children's Core for Biomedical Research. Her research interests include the design and analysis of clinical trials, with emphasis in the pediatric and orphan disease setting. She is involved in the development of new clinical outcome measures for cystic fibrosis and, in particular, the validation of biomarkers to enable early evaluation of new therapies. Dr. Hamblett also provides statistical training to clinical researchers and scientists, with applications to both the preclinical and clinical fields.

Overview

Research Focus Area

Translational Research

Awards and Honors

Award Name Award Description Awarded By Award Date
National Institute of Health Pre-Doctoral Fellow University of Washington Center for AIDS and STD Research, Seattle WA 1996 - 1999
Pi Mu Epsilon, Mathematics Honor Society Santa Clara University 1994
Sigma Xi, Scientific Research Society Santa Clara University 1994
Alpha Sigma Nu, Jesuit Honor Society Santa Clara University 1994
George W. Evans Memorial Award For outstanding work in mathematical writing and research. Santa Clara University 1994
Presidential Scholarship recipient Santa Clara University 1994
Dean's List Santa Clara University 1990 - 1994

Publications

  • Mayer-Hamblett N, Kronmal RA, Gibson RL, Rosenfeld M, Retsch-Bogart G, Treggiari MM, Burns JL, Khan U, Ramsey BW, for the EPIC Investigators
    Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis.
    Pediatric pulmonology , 2012 Feb. : 125-134
  • Simon TD, Whitlock KB, Riva-Cambrin J, Kestle JR, Rosenfeld M, Dean JM, Holubkov R, Langley M, Mayer-Hamblett N
    Association of intraventricular hemorrhage secondary to prematurity with cerebrospinal fluid shunt surgery in the first year following initial shunt placement.
    Journal of Neurosurgery. Pediatrics , 2012 Jan. : 54-63
  • Quon BS, Mayer-Hamblett N, Aitken ML, Goss CH
    Risk of Post Lung Transplant Renal Dysfunction in Adults with Cystic Fibrosis.
    Chest , 2012 Jan.
  • Quon BS, Mayer-Hamblett N, Aitken ML, Smyth AR, Goss CH
    Risk factors for chronic kidney disease in adults with cystic fibrosis.
    American journal of respiratory and critical care medicine , 2011 Nov. : 1147-52
  • Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N, Khan U, Kulich M, Kronmal R, Williams J, Hiatt P, Gibson RL, Spencer T, Orenstein D, Chatfield BA, Froh DK, Burns JL, Rosenfeld M, Ramsey BW, Early Pseudomonas Infection Control (EPIC) Investigators
    Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis.
    Archives of pediatrics & adolescent medicine , 2011 Sept. : 847-56
  • Tuan TJ, Thorell EA, Hamblett NM, Kestle JR, Rosenfeld M, Simon TD
    Treatment and microbiology of repeated cerebrospinal fluid shunt infections in children.
    The Pediatric infectious disease journal , 2011 Sept. : 731-5
  • Green N, Burns JL, Mayer-Hamblett N, Kloster M, Lands LC, Anstead M, Ratjen F, Saiman L
    Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis.
    Journal of clinical microbiology , 2011 July : 2772-3
  • Rogers GB, Hoffman LR, Johnson MW, Mayer-Hamblett N, Schwarze J, Carroll MP, Bruce KD
    Using bacterial biomarkers to identify early indicators of cystic fibrosis pulmonary exacerbation onset.
    Expert review of molecular diagnostics , 2011 Mar. : 197-206
  • Nicole Hamblett, PhD
    Open-label, Follow-On Study to Assess Continued Efficacy and Safety of Azithromycin in Children and Adolescents with CF Uninfected with Pseudomonas aeruginosa.
    Pediatric Pulmonology (In press) , 2011
  • Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, Sagel SD, Hornick DB, Konstan MW, Donaldson SH, Moss RB, Pilewski JM, Rubenstein RC, Uluer AZ, Aitken ML, Freedman SD, Rose LM, Mayer-Hamblett N, Dong Q, Zha J, Stone AJ, Olson ER, Ordoñez CL, Campbell PW, Ashlock MA, Ramsey BW
    Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation.
    The New England journal of medicine , 2010 Nov. : 1991-2003
  • Solomon GM, Konstan MW, Wilschanski M, Billings J, Sermet-Gaudelus I, Accurso F, Vermeulen F, Levin E, Hathorne H, Reeves G, Sabbatini G, Hill A, Mayer-Hamblett N, Ashlock M, Clancy JP, Rowe SM
    An international randomized multicenter comparison of nasal potential difference techniques.
    Chest , 2010 Oct. : 919-28
  • Saiman L, Anstead M, Mayer-Hamblett N, Lands LC, Kloster M, Hocevar-Trnka J, Goss CH, Rose LM, Burns JL, Marshall BC, Ratjen F, AZ0004 Azithromycin Study Group
    Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.
    JAMA : the journal of the American Medical Association , 2010 May : 1707-15
  • Ashlock MA, Beall RJ, Hamblett NM, Konstan MW, Penland CM, Ramsey BW, Van Dalfsen JM, Wetmore DR, Campbell PW 3rd
    A pipeline of therapies for cystic fibrosis.
    Seminars in respiratory and critical care medicine , 2009 Oct. : 611-26
  • Treggiari MM, Rosenfeld M, Mayer-Hamblett N, Retsch-Bogart G, Gibson RL, Williams J, Emerson J, Kronmal RA, Ramsey BW, EPIC Study Group
    Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'.
    Contemporary clinical trials , 2009 May : 256-68
  • Sanders DB, Rosenfeld M, Mayer-Hamblett N, Stamey D, Redding GJ
    Reproducibility of spirometry during cystic fibrosis pulmonary exacerbations.
    Pediatric pulmonology , 2008 Nov. : 1142-6
  • Moskowitz SM, Silva SJ, Mayer-Hamblett N, Pasta DJ, Mink DR, Mabie JA, Konstan MW, Wagener JS, Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis (ESCF)
    Shifting patterns of inhaled antibiotic use in cystic fibrosis.
    Pediatric pulmonology , 2008 Sept. : 874-81
  • Mayer-Hamblett N, Ramsey BW, Kronmal RA
    Advancing outcome measures for the new era of drug development in cystic fibrosis.
    Proceedings of the American Thoracic Society , 2007 Aug. : 370-7
  • Gibson RL, Emerson J, Mayer-Hamblett N, Burns JL, McNamara S, Accurso FJ, Konstan MW, Chatfield BA, Retsch-Bogart G, Waltz DA, Acton J, Zeitlin P, Hiatt P, Moss R, Williams J, Ramsey BW
    Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis.
    Pediatric pulmonology , 2007 July : 610-23
  • Clancy JP, Rowe SM, Bebok Z, Aitken ML, Gibson R, Zeitlin P, Berclaz P, Moss R, Knowles MR, Oster RA, Mayer-Hamblett N, Ramsey B
    No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations.
    American journal of respiratory cell and molecular biology , 2007 July : 57-66
  • Nguyen D, Emond MJ, Mayer-Hamblett N, Saiman L, Marshall BC, Burns JL
    Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes.
    Pediatric pulmonology , 2007 June : 533-41
  • Goss CH, Mayer-Hamblett N, Kronmal RA, Williams J, Ramsey BW
    Laboratory parameter profiles among patients with cystic fibrosis.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society , 2007 Apr, : 117-23
  • Mayer-Hamblett N, Aitken ML, Accurso FJ, Kronmal RA, Konstan MW, Burns JL, Sagel SD, Ramsey BW
    Association between pulmonary function and sputum biomarkers in cystic fibrosis.
    American journal of respiratory and critical care medicine , 2007 Apr, : 822-8
  • Saiman L, Mayer-Hamblett N, Campbell P, Marshall BC, Macrolide Study Group
    Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis.
    American journal of respiratory and critical care medicine , 2005 Oct. : 1008-12
  • Moss RB, Mayer-Hamblett N, Wagener J, Daines C, Hale K, Ahrens R, Gibson RL, Anderson P, Retsch-Bogart G, Nasr SZ, Noth I, Waltz D, Zeitlin P, Ramsey B, Starko K
    Randomized, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b in patients with mild to moderate cystic fibrosis lung disease.
    Pediatric pulmonology , 2005 Mar. : 209-18
  • Mayer-Hamblett N, Kronmal RA
    Improving the estimation of change from baseline in a continuous outcome measure in the clinical trial setting.
    Contemporary clinical trials , 2005 Feb. : 2-16
  • Beckmann C, Brittnacher M, Ernst R, Mayer-Hamblett N, Miller SI, Burns JL
    Use of phage display to identify potential Pseudomonas aeruginosa gene products relevant to early cystic fibrosis airway infections.
    Infection and immunity , 2005 Jan. : 444-52
  • Goss CH, Mayer-Hamblett N, Aitken ML, Rubenfeld GD, Ramsey BW
    Association between Stenotrophomonas maltophilia and lung function in cystic fibrosis.
    Thorax , 2004 Nov. : 955-9
  • Moss RB, Rodman D, Spencer LT, Aitken ML, Zeitlin PL, Waltz D, Milla C, Brody AS, Clancy JP, Ramsey B, Hamblett N, Heald AE
    Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial.
    Chest , 2004 Feb. : 509-21
  • Ordoñez CL, Henig NR, Mayer-Hamblett N, Accurso FJ, Burns JL, Chmiel JF, Daines CL, Gibson RL, McNamara S, Retsch-Bogart GZ, Zeitlin PL, Aitken ML
    Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis.
    American journal of respiratory and critical care medicine , 2003 Dec. : 1471-5
  • Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, Coquillette S, Fieberg AY, Accurso FJ, Campbell PW 3rd, Macrolide Study Group
    Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.
    JAMA : the journal of the American Medical Association , 2003 Oct. : 1749-56
  • Piedra PA, Cron SG, Jewell A, Hamblett N, McBride R, Palacio MA, Ginsberg R, Oermann CM, Hiatt PW, Purified Fusion Protein Vaccine Study Group
    Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: a multi-center trial in children with cystic fibrosis.
    Vaccine , 2003 June : 2448-60
  • Smith AL, Fiel SB, Mayer-Hamblett N, Ramsey B, Burns JL
    Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis.
    Chest , 2003 May : 1495-502
  • Gibson RL, Emerson J, McNamara S, Burns JL, Rosenfeld M, Yunker A, Hamblett N, Accurso F, Dovey M, Hiatt P, Konstan MW, Moss R, Retsch-Bogart G, Wagener J, Waltz D, Wilmott R, Zeitlin PL, Ramsey B
    Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis.
    American journal of respiratory and critical care medicine , 2003 Mar. : 841-9
  • Goss CH, Mayer-Hamblett N, Kronmal RA, Ramsey BW
    The cystic fibrosis therapeutics development network (CF TDN): a paradigm of a clinical trials network for genetic and orphan diseases.
    Advanced drug delivery reviews , 2002 Dec. : 1505-28
  • Mayer-Hamblett N, Rosenfeld M, Emerson J, Goss CH, Aitken ML
    Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality.
    American journal of respiratory and critical care medicine , 2002 Dec. : 1550-5
  • Cieri MV, Mayer-Hamblett N, Griffith A, Burns JL
    Correlation between an in vitro invasion assay and a murine model of Burkholderia cepacia lung infection.
    Infection and immunity , 2002 Mar. : 1081-6
  • Noone PG, Hamblett N, Accurso F, Aitken ML, Boyle M, Dovey M, Gibson R, Johnson C, Kellerman D, Konstan MW, Milgram L, Mundahl J, Retsch-Bogort G, Rodman D, Williams-Warren J, Wilmott RW, Zeitlin P, Ramsey B, Cystic Fibrosis Therapeutics Development Research Group
    Safety of aerosolized INS 365 in patients with mild to moderate cystic fibrosis: results of a phase I multi-center study.
    Pediatric pulmonology , 2001 Aug. : 122-8
  • Mayer-Hamblett N, Self S
    A regression modeling approach for describing patterns of HIV genetic variation.
    Biometrics , 2001 June : 449-60
  • Nicole Hamblett, PhD
    Revision surgeries are associated with significant increased risk of subsequent cerebrospinal fluid shunt infection
    Pediatric Disease Journal (In press)

Research Funding

Grant Title Grantor Amount Award Date
Rates of Hemoptysis Among Individuals with Cystic Fibrosis Enrolled in Clinical Trials Pharmaxis Ltd. Feb. 1, 2014
Long Term Outcomes After Eradication of Pseudomonas Aeruginosa Among Children Enrolled in EPIC Clinical Novartis Pharmaceuticals Corp. Dec. 15, 2013
Optimizing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE NIH/NHLBI Sept. 15, 2013
G551D Observational Study Expanded to Include Additional Genotypes and Extended for Long Term Followup Cystic Fibrosis Foundation Therapeutics Sept. 1, 2013
A Multicenter Study of the Effects of AquADEKs-2 on Markers of Inflammation and Oxidative Stress in CF Cystic Fibrosis Foundation Therapeutics Aug. 1, 2012
Pseudomonas Aeruginosa Adaptation During Early CF Airway Infection and Treatment NIH Sept. 11, 2009
Institute of Translational Health Sciences NIH/NCATS Sept. 17, 2007